Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of “Buy” from Analysts

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been given an average recommendation of “Buy” by the seven ratings firms that are currently covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $86.00.

Several research analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a report on Friday, March 1st. Truist Financial reissued a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a report on Wednesday, March 13th. William Blair reissued an “outperform” rating on shares of Keros Therapeutics in a report on Wednesday, February 21st. Piper Sandler reissued an “overweight” rating and set a $105.00 price objective on shares of Keros Therapeutics in a report on Wednesday, March 27th. Finally, Wedbush reissued an “outperform” rating and set a $86.00 price objective on shares of Keros Therapeutics in a report on Thursday, February 29th.

Keros Therapeutics Stock Performance

Shares of Keros Therapeutics stock opened at $60.26 on Tuesday. The stock has a market capitalization of $2.17 billion, a PE ratio of -11.59 and a beta of 1.32. Keros Therapeutics has a 52-week low of $27.02 and a 52-week high of $73.00. The company has a 50-day simple moving average of $63.18 and a two-hundred day simple moving average of $49.37.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Friday, March 1st. The company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $0.03. The firm had revenue of $0.14 million during the quarter. During the same period in the previous year, the business earned ($1.09) earnings per share. As a group, equities research analysts forecast that Keros Therapeutics will post -5.11 EPS for the current fiscal year.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KROS. China Universal Asset Management Co. Ltd. boosted its position in shares of Keros Therapeutics by 356.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,460 shares of the company’s stock worth $138,000 after purchasing an additional 2,702 shares during the period. Arizona State Retirement System bought a new position in shares of Keros Therapeutics in the fourth quarter worth approximately $231,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Keros Therapeutics by 8.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,494 shares of the company’s stock worth $398,000 after purchasing an additional 950 shares during the period. Perpetual Ltd bought a new position in shares of Keros Therapeutics in the first quarter worth approximately $443,000. Finally, Principal Financial Group Inc. boosted its position in shares of Keros Therapeutics by 8.8% in the first quarter. Principal Financial Group Inc. now owns 7,063 shares of the company’s stock worth $468,000 after purchasing an additional 574 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.